Skip to content

Trial · Interventional

RecruitingNot applicableRegistry data

Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders

Short name DT-HCG-IVF

NCTNCT07861399 (opens ClinicalTrials.gov in a new tab)Other idObs-Gyn-1000/2026/07/0020
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Recruiting
Phase
Not applicable
Enrollment
100 participants (estimated)
Sponsor
Al-Azhar University · Other
Design
Randomized · Single masking
Countries
1 country

Egypt

Start
1 Sept 2026
Primary completion
Aug 2028 (estimated)
Completion
Oct 2028 (estimated)
First posted
6 Oct 2026
Last update posted
6 Oct 2026
Conditions
ICSI · IVF · Normal Responders · Infertility Assisted Reproductive Technology · Infertile Women Undergoing IVF or ICSI · Infertile Women Undergoing ART · Triggering Ovulation · Oocyte Maturation

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2026202720282029
  1. N/A

    DT-HCG-IVF

    NCT07861399

    1 Sept 2026 to est. Oct 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

To compare the embryological and reproductive outcomes of dual trigger versus conventional hCG trigger for final oocyte maturation in normal responder patients undergoing ICSI cycles.

Interventions

  • Dual trigger (human chorionic gonadotropin plus GnRH-agonist)Drug
  • hCG triggerDrug

Arms2

  • Experimental

    Dual Trigger

    Dual Trigger Group: Participants will receive a GnRH agonist combined with hCG

  • Active comparator

    HCG Trigger

    HCGTrigger Group: Participants will receive hCG alone.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Oocytes Maturation

    Time frame · From oocyte retrieval until completion of oocyte assessment, approximately 0-2 hours after retrieval.

    Registry description

    Percentage of retrieved oocytes that are at the metaphase II (MII) stage.

Secondary outcomes(6)

  1. Number of MII oocytes

    Time frame · At oocyte retrieval (Day 0), approximately 0-2 hours after oocyte pick up.

    Registry description

    Number of metaphase II oocytes retrieved

  2. Number of oocytes retrieved

    Time frame · Day of oocyte retrieval (Day 0) after oocyte retrieval.

    Registry description

    Total number of oocytes retrieved during oocyte retrieval.

  3. Fertilization rate

    Time frame · Approximately 16-18 hours after insemination/ICSI

    Registry description

    Percentage of normally fertilized mature oocytes (2PN)

  4. Embryo utilization rate

    Time frame · Day 3-5 after oocyte retrieval

    Registry description

    Percentage of normally fertilized oocytes resulting in embryos suitable for transfer or cryopreservation

  5. Clinical pregnancy rate

    Time frame · Approximately 5-7 weeks after embryo transfer

    Registry description

    Percentage of embryo transfer cycles resulting in an intrauterine gestational sac with fetal cardiac activity

  6. Incidence of ovarian hyperstimulation syndrome (OHSS)

    Time frame · From the day of trigger administration until 14 days after oocyte retrieval

    Registry description

    Proportion of participants developing OHSS following controlled ovarian stimulation and oocyte retrieval, classified according to predefined diagnostic/severity criteria.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

PubMed tag: none · 2017

4 results

Final follicular maturation by administration of GnRH agonist plus HCG versus HCG in normal responders in ART cycles: An RCT.

Eftekhar et al. 2017International journal of reproductive biomedicinecited by 24

PMID 29177244PMC5601934DOI 10.29252/ijrm.15.7.429PUB-29177244

CC BY4 results
Download PDFSee results (4)

Eligibility

Who could join, as posted.

Sex
Female
Age
from 20 Years up to 40 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Women aged 20-40 years. * Body mass index (BMI) between 18 and 30 kg/m². * Undergoing ICSI treatment using a GnRH antagonist protocol. * Normal ovarian reserve and expected normal ovarian response. * AMH between 1.2 - 3.5 ng/ml * AFC 7-15 follicle. * First or second ICSI cycle. Exclusion Criteria: * Poor ovarian response (Bologna/POSEIDON criteria) * High ovarian response with a risk of ovarian hyperstimulation syndrome (OHSS) AMH \> 3.5 ng/ml or AFC \> 15 follicle. * Polycystic ovary syndrome (PCOS). * Serum E2 level \> 3500 pg/ml at day of triggering. * Endocrine disorders including diabetes mellitus, thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, or Cushing syndrome. * Congenital uterine abnormalities. * Severe systemic diseases affecting fertility outcomes.

PepBank is a research reference. Talk to a doctor before you use any peptide.